Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

3M Aldara for keratosis

Executive Summary

FDA clears 3M's Aldara supplemental NDA March 2 for the treatment of clinically typical, nonhyperkeratonic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Aldara cream (imiquimod) is the first immune response modifier approved for actinic keratoses. The drug was approved for the treatment of external genital and perianal warts in 1997. FDA is reviewing an sNDA for superficial basal call carcinoma, 3M says...

You may also be interested in...



3M Aldara “approvable” for carcinoma

3M projects approval of Aldara (imiquimod) cream for superficial basal cell carcinoma in second half of 2004 following receipt of "approvable" letter. Company will provide additional safety data per FDA's request without conducting additional trials. The drug was first cleared in 1997 for external genital and perianal warts and was approved March 2 for actinic keratoses (1"The Pink Sheet" March 8, 2004, In Brief)...

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel